Antiparkinson Agents
Research News and Information

Sunday, November 22, 2009

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.

Nov 2009 OBJECTIVE: To investigate the incidence of and risk factors for cognitive impairment in a large, well-defined clinical trial cohort of patients with early Parkinson disease (PD). METHODS: The Mini-Mental State Examination (MMSE) was administered ... Read more...

[Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review]

3 Oct 2009 The Cochrane analysis confirms some well-known facts: initial therapy with dopamine agonists (DA) delays the incidence of motor complications, but is associated with inferior motor control and a higher frequency of non-motor adverse events (AE) ... Read more...

Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease.

17 Sep 2009 OBJECTIVES: The aims of this study were: to investigate the postexcitatory inhibition of cortical evoked potentials on auditory paired-click stimulation in patients with Parkinson's disease (PD), to analyze the correlation of N1-P2 amplitude ratios ... Read more...

Latest indexed articles for 'Antiparkinson Agents'

These are the very latest articles for this heading:

• Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Nov 2009
• [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review] 3 Oct 2009
• Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease. 17 Sep 2009
• Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. 14 Sep 2009
• Drug-induced compulsive behaviors: exceptions to the rule. 30 Aug 2009
• Does subthalamotomy have a place in the treatment of Parkinson's disease? 30 Aug 2009
• [Management of Parkinson's disease in 2009] 24 Aug 2009
• A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. 22 Aug 2009
• Drug-induced fibrotic valvular heart disease. 13 Aug 2009
• Heat waves and the elderly. Drugs for Parkinson's disease. 2 Aug 2009
• Bilateral effects of unilateral subthalamic deep brain stimulation on Parkinson's disease at 1 year. 30 Jul 2009
• [Parkinson's disease and obsessive-compulsive spectrum] 30 Jul 2009
• Treatment disparities in Parkinson's disease. 30 Jul 2009
• Drug-induced dyskinesias. 30 Jul 2009
• Medical treatment of Parkinson disease. 30 Jul 2009
• Visualizing vesicular dopamine dynamics in Parkinson's disease. 30 Jul 2009
• Neuropsychiatric disorders in early untreated Parkinson's disease. 30 Jul 2009
• Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. 28 Jul 2009
• Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. 19 Jul 2009
• Thwarting dyskinesia by targeting mTORC1. 19 Jul 2009

See a longer list of these articles.

Technical information about 'Antiparkinson Agents'

Definition: Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Registry Number: 0

Descriptor UI: D000978

Alternative terms: Antiparkinson Agents; Agents, Antiparkinson; Antiparkinsonian Agents; Agents, Antiparkinsonian; Antiparkinsonians; Antiparkinson Drugs; Drugs, Antiparkinson;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.427.090.050;

Online Note: use ANTIPARKINSON AGENTS to search ANTIPARKINSON DRUGS 1972-75 (as Prov 1972) & PARASYMPATHOLYTICS 1966-71

History Note: 76; was ANTIPARKINSON DRUGS 1972-75 (Prov 1972); was ANTIPARKINSON DRUGS see under PARASYMPATHOLYTICS 1963-72

Technical Notes: GEN or unspecified; prefer specifics; consider also PARKINSON DISEASE /drug ther